<DOC>
	<DOCNO>NCT00410358</DOCNO>
	<brief_summary>This study assess tolerability , safety , efficacy pharmacokinetics gimatecan Japanese patient . Gimatecan administer orally five consecutive day , every 28 day , adult patient advance solid tumor progress despite standard therapy standard systemic therapy exist .</brief_summary>
	<brief_title>A Dose Escalation Gimatecan Administered Orally Japanese Patients With Advanced Solid Tumor .</brief_title>
	<detailed_description />
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients histological cytological confirm advanced solid tumor , progress despite standard therapy standard therapy exist . Life expectancy least 3 month Adequate hematological parameter No major impairment renal hepatic function Gastrointestinal dysfunction , gastrectomy malabsorption syndrome could alter absorption . Patients receive investigational compound within past 28 day . Patients antineoplastic therapy within last 28 day . Patients know HIV hepatitis virus positive , patient presence active suspect acute chronic uncontrolled infection Patients history allergy camptothecin family drug . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Gimatecan</keyword>
	<keyword>topoisomerase I inhibitor</keyword>
	<keyword>advanced solid tumor</keyword>
</DOC>